Pfizer and BioNTech are working to develop an mRNA-based shingles vaccine following the success of the COVID-19 shot. This latest collaboration will mark the third time the pharmaceutical companies have worked together on a vaccine.
Bill Adams, Chief U.S. Economist at Fifth Third Bank, breaks down the Fed's latest decision, inflation risks, and what Kevin Warsh's debut means for markets.
Lou Whiteman, Contributing Aerospace Analyst at The Motley Fool, discusses SpaceX's volatile first week of trading and what investors should watch next.
